The effects of SIRPα blockade were not limited to melanoma and translated to other solid tumors, namely pancreatic and breast tumors showing a conserved anti-phagocytic pathway activated in suppressive myeloid cells across multiple tumor types. Here, SIRPA is linked to melanoma.